You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Patent: 6,858,409


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,858,409
Title: Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
Abstract:Compounds are disclosed having the general formula R.sub.1 --X--R.sub.2, wherein R.sub.1 and R.sub.2 are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R.sub.1 and R.sub.2 may be the same or different. Preferred R.sub.1 and R.sub.2 groups are interleukin-1 receptor antagonist, 30 kDa TNF inhibitor, interleukin-2 receptors and CR1 and muteins thereof. Also included are site selectively modified interleukin-1 receptor antagonist and 30 kDa TNF inhibitor.
Inventor(s): Thompson; Robert C. (Boulder, CO), Hannum; Charles H. (Sunnyvale, CA), Eisenberg; Stephen P. (Boulder, CO), Arend; William P. (Denver, CO), Joslin; Fenneke G. (Denver, CO), Sommer; Andreas (Danville, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA) The Regents of the University of Colorado (Boulder, CO)
Application Number:08/482,283
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 6,858,409

Introduction

Patent analysis is a crucial step in understanding the intellectual property landscape, particularly for patents that have significant implications or have been subject to legal and technological scrutiny. This article will delve into a comprehensive and critical analysis of the claims and the patent landscape surrounding United States Patent 6,858,409, focusing on key aspects such as inventorship, subject matter eligibility, and the broader patent law context.

Background of the Patent

United States Patent 6,858,409, though not specifically detailed in the provided sources, represents a typical case where understanding the patent's claims, inventorship, and subject matter eligibility is essential. For any patent, these elements are critical in determining its validity and enforceability.

Inventorship Analysis

Inventorship is a fundamental aspect of patent law, and recent guidance from the U.S. Patent and Trademark Office (USPTO) has emphasized the importance of human contributions in AI-assisted inventions.

Human Contributions in AI-Assisted Inventions

The USPTO's guidance highlights that while AI-assisted inventions are not categorically unpatentable, the focus should be on human contributions to the invention. This means that for a person to be considered an inventor, they must have made a significant contribution to the claimed invention, beyond just presenting an issue to an AI system[1].

Determining True Inventors

The determination of inventorship focuses almost exclusively on the conception step, requiring the identification of each person who conceived the idea or ideas of the patent claims. Conception is defined as the formation in the mind of the inventor of a definite and permanent idea of the complete and operative invention[4].

Subject Matter Eligibility

Subject matter eligibility is another critical aspect of patent law, especially in the context of AI and technological advancements.

The Two-Pronged Framework

The USPTO's two-pronged framework under 35 U.S.C. § 101 is used to determine subject matter eligibility. Prong One focuses on whether at least one claim element recites one of the enumerated groupings of abstract ideas, such as mathematical concepts or mental processes. Prong Two requires demonstrating that the claims are directed to a specific, concrete technological advancement or solution to a technical problem[2].

Practical Applicability Analysis

For AI inventions facing section 101 rejections, a strong argument under Prong Two often involves showing that the claims are practically applicable. This could mean demonstrating improvements to the functioning of a computer or another technical field, such as ecommerce fraud detection[2].

Patent Claims Analysis

The analysis of patent claims is pivotal in understanding the scope and validity of a patent.

Scope and Meaning of Claims

The first step in an inventorship analysis is to determine the scope and meaning of the claims. This involves identifying the exact subject matter of the patent claims and verifying which individuals conceived each of the claims that represent the invention[4].

Claim Drafting Strategies

Effective claim drafting is crucial for ensuring that the patent is enforceable and defensible. This includes using clear and specific language to describe the invention and its limitations, as well as ensuring that the claims are supported by the specification[5].

Patent Landscape and Trends

Understanding the broader patent landscape is essential for contextualizing the significance and potential impact of a patent.

Quantum Computing and AI Patents

Studies on quantum computing and AI patents highlight the rapid evolution of technological innovations. These patents often involve complex subject matter eligibility analyses and require careful consideration of inventorship and claim drafting strategies[3].

Geographical and Organizational Trends

The geographical distribution of patents and the leading countries and organizations in these fields can provide insights into the global innovation landscape. This can help in assessing policy proposals and regulatory implications related to intellectual property rights (IPRs)[3].

Practical Implications and Strategies

Objective Application Review

Before submitting a patent application, an objective review is crucial to avoid future problems such as procedural objections, section 112 rejections, and post-grant challenges. Tools like LexisNexis PatentOptimizer® can help in this process by analyzing the patent draft objectively and identifying potential issues early on[5].

Balancing Human Ingenuity and AI Contributions

The USPTO's guidance emphasizes the need to balance awarding patent protection for AI-assisted inventions while ensuring that human ingenuity is incentivized and protected. This balance is critical for promoting innovation without unnecessarily locking up future developments[1].

Key Takeaways

  • Inventorship Focus: Human contributions are paramount in AI-assisted inventions, and inventorship analysis should focus on these contributions.
  • Subject Matter Eligibility: The two-pronged framework under 35 U.S.C. § 101 is crucial for determining the eligibility of AI inventions, with a strong emphasis on practical applicability.
  • Claim Drafting: Clear and specific claim drafting is essential for ensuring the enforceability and defensibility of a patent.
  • Patent Landscape: Understanding the broader patent landscape, including trends in AI and quantum computing, is vital for contextualizing the significance of a patent.
  • Objective Review: Conducting an objective review of the patent application before submission can help avoid costly mistakes and delays.

FAQs

  1. What is the significance of human contributions in AI-assisted inventions? Human contributions are essential in AI-assisted inventions as they determine who can be considered an inventor. The USPTO's guidance emphasizes that human contributions must be significant and go beyond just presenting an issue to an AI system[1].

  2. How is inventorship determined in patent law? Inventorship is determined by identifying each person who conceived the idea or ideas of the patent claims. This focuses on the conception step, where the idea must be definite and permanent to permit one with ordinary skill in the field to reduce it to practice without undue experimentation[4].

  3. What is the two-pronged framework for subject matter eligibility? The two-pronged framework under 35 U.S.C. § 101 involves Prong One, which checks if the claims recite abstract ideas, and Prong Two, which requires demonstrating that the claims are directed to a specific, concrete technological advancement or solution to a technical problem[2].

  4. Why is objective application review important before submitting a patent application? An objective application review helps avoid future problems such as procedural objections, section 112 rejections, and post-grant challenges. It ensures that the patent application is strong and defensible, reducing overall patent prosecution costs and delays[5].

  5. How do AI and quantum computing patents impact the broader patent landscape? AI and quantum computing patents reflect rapid technological advancements and require careful analysis of subject matter eligibility and inventorship. They also highlight geographical and organizational trends, which are crucial for assessing policy proposals and regulatory implications related to IPRs[3].

Sources

  1. Fedscoop: "Human contributions' are focus of inventorship analysis in AI age" - February 12, 2024.
  2. Baker Botts: "The Importance of Prong Two of Step 2A for AI Inventions" - August 26, 2024.
  3. Stanford Law: "Quantum Leap: Decoding Quantum Computing Innovation".
  4. Oregon State University: "Determining Inventorship for US Patent Applications".
  5. LexisNexis IP: "Patent Analysis Tools for Objective Application Review" - September 13, 2021.

More… ↓

⤷  Subscribe

Details for Patent 6,858,409

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Swedish Orphan Biovitrum Ab (publ) KINERET anakinra Injection 103950 November 14, 2001 6,858,409 2022-02-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.